Furmonertinib irreversibly inhibits mutant EGFR kinase (e.g., covalent binding at Cys797), blocking EGFR phosphorylation and downstream MAPK/PI3K–AKT signaling, leading to growth arrest and apoptosis of EGFR-mutant tumor cells (including T790M).